Скачать или смотреть Ongoing studies of elranatamab in frail patients & with DaraPomDex: MagnetisMM-3 & MagnetisMM-5

Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, gives an overview of two posters on elranatamab from this year's EHA meeting. The first one evaluated the safety and efficacy of elranatamab in frail and elderly patients with relapsed/refractory (R/R) multiple myeloma from MagnetisMM-3 (NCT04649359) and showed that elranatamab had a manageable safety profile and was effective in this patient population. The second poster was about the MagnetisMM-5 study (NCT05020236) investigating elranatamab monotherapy versus elranatamab plus daratumumab, pomalidomide, and dexamethasone in patients who have received at least one prior line of therapy (LOT). Prof. Leleu also notes that elranatamab is also going to be evaluated in the upfront setting in transplant-ineligible patients. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.